Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 12;104(8):1325-33.
doi: 10.1038/bjc.2011.104. Epub 2011 Mar 29.

Markers for the non-invasive diagnosis of mesothelioma: a systematic review

S van der Bij  1 , E Schaake, H Koffijberg, J A Burgers, B A J M de Mol, K G M Moons
Affiliations

Markers for the non-invasive diagnosis of mesothelioma: a systematic review

S van der Bij et al. Br J Cancer. .

Abstract

Background: Numerous markers have been evaluated to facilitate the non-invasive diagnostic work-up of mesothelioma. The purpose of this study was to conduct a structured review of the diagnostic performance of non-invasive marker tests for the detection of mesothelioma in patients with suspected mesothelioma.

Methods: Studies on the diagnostic accuracy of serum and cytological markers published till 31 December 2009, available in either PUBMED or Embase, to detect or exclude the presence of mesothelioma were extracted. Study quality was assessed with use of the Quadas criteria.

Results: In total, 82 articles were included in this systemic review. Overall, quality of the incorporated studies to address our objective was poor. The most frequently studied immunohistochemical markers for cytological analysis were EMA, Ber-Ep4, CEA, and calretinin. The most frequently investigated serum marker was soluble mesothelin-related protein (SMRP). The markers CEA, Ber-EP4, and calretinin were most valuable in discriminating mesothelioma from other malignant diseases. Markers EMA and SMRP were most valuable in discriminating mesothelioma from non-malignant diseases. No marker performed well in discriminating between mesothelioma and all other diseases.

Conclusion: Currently, there is only limited evidence to properly assess the value of non-invasive marker tests in the diagnosis of mesothelioma. Studies were of limited value to address our objective and results showed considerable unexplained study heterogeneity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the selection of the relevant articles. Serum and effusion markers include tests to detect serum and effusion marker levels; immunohistochemical markers include marker tests used for cytological analysis of effusion samples; genetic markers include polymerase chain reaction tests to detect specific gene expressions or fluorescence in situ hybridisation (FISH) tests to detect gene deletions with the use of specialised gene probes.
Figure 2
Figure 2
Summary of quality of the included studies according to the Quadas criteria (see Supplementary Appendix).
Figure 3
Figure 3
Sensitivity against 1-specificity in ROC space to discriminate mesothelioma from other malignant diseases. The height of the blocks is proportional to the reciprocal of the number of mesothelioma patients (mesothelioma yes subjects) and the width of the blocks is proportional to the reciprocal of the number of patients with other malignant diseases (mesothelioma no subjects).
Figure 4
Figure 4
Sensitivity against 1-specificity in ROC space to discriminate mesothelioma from non-malignancy. The height of the blocks is proportional to the reciprocal of the number of mesothelioma patients (mesothelioma yes subjects) and the width of the blocks is proportional to the reciprocal of the number of non-malignant patients (mesothelioma no subjects).
See this image and copyright information in PMC

References

    1. Begg CB, Greenes RA (1983) Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39: 207–215 - PubMed
    1. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KG (2008) Advantages of the nested case-control design in diagnostic research. BMC Med Res Methodol 8: 48. - PMC - PubMed
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003a) Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol 119: 18–22 - PubMed
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG (2003b) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49: 7–18 - PubMed
    1. Creaney J, Robinson BW (2009) Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 15: 366–370 - PubMed

Substances